[The pharmacology of 13,14-dihydro-PGE1 in comparison with PGE1].
This study investigates the effects of 13,14-Dihydro-PGE1 (PGE0) in comparison to PGE1 on human platelets, human polymorphonuclear granulocytes (PMN) and a number of vessel preparations of different species. The potency of PGE0 in inhibition of platelet and neutrophil activation is similar to PGE1. The vascular action differs. At a comparable molar potency, PGE0 showed stronger contractile and less relaxing effects than PGE1. The biological activities of PGE0 may contribute to the in vivo effects of PGE1 in treatment of peripheral arterial occlusive disease, in particular at high-dose i.v. administration.
Braun
M
M
Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf.
Ney
P
P
Hohlfeld
T
T
Szymanski
C
C
Bruch
L
L
Schrör
K
K
D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D014661:Vasoconstriction / Q000187:drug effects
C069881:13,14-dihydroprostaglandin E1; D000527:Alprostadil
Pharmakologie von 13,14-Dihydro-PGE1 im Vergleich zu PGE1.